Abstract
BackgroundEULAR recommends initiation of biologic agents in combination with MTX in pts with RA after failure of conventional synthetic (cs)DMARDs and in the presence of poor prognostic factors. In addition,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
